Rebranding Lipophilic Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rebranding Lipophilic Excipients
Streamlining the structure, nomenclature and functionality of excipients


Pharmaceutical Technology Europe
Volume 24, Issue 9

Conclusion

Rebranding gives us the opportunity to include other solubilizers and related excipients based on their chemistry and functionalities in our four umbrella subgroups. With continuing interest to increase drug solubilization, it is our understanding that this rebranding will reduce the complexity involved in selecting pharmaceuticalgrade excipients in formulation development. Thus, this will encourage excipients manufacturers to adopt a norm to simplify complex product portfolios.

Reference

1. C.J.H. Porter, C.W. Pouton, J.F. Cuine and W.N. Charman, Adv. Drug Delivery Rev. 60 (6), 673–691 (2008).




Download your free copy of BASF's solubility enhancement compendium at: http://www.innovate-excipients.basf.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here